Patents by Inventor Gro Klitgaard Povlsen

Gro Klitgaard Povlsen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Bifunctional compounds comprising insulin peptides and EGF(A) peptides
    Patent number: 11649269
    Abstract: The present invention relates to novel covalently linked bi-functional fusion proteins comprising insulin and EGF(A) analogues or derivatives thereof, and their pharmaceutical use. Furthermore, the invention relates to pharmaceutical compositions comprising such bi-functional compounds, and to the use of such compounds for the treatment or prevention of medical conditions relating to diabetes and dyslipidaemia associated with diabetes.
    Type: Grant
    Filed: October 4, 2019
    Date of Patent: May 16, 2023
    Assignee: Novo Nordisk A/S
    Inventors: Martin Werner Borchsenius Muenzel, Susanne Hostrup, Gro Klitgaard Povlsen, Mathias Norrman, Thomas Boerglum Kjeldsen, Claudia Ulrich Hjoerringgaard, Peter Madsen
  • BIFUNCTIONAL COMPOUNDS COMPRISING INSULIN PEPTIDES AND EGF(A) PEPTIDES
    Publication number: 20220009989
    Abstract: The present invention relates to novel covalently linked bi-functional fusion proteins comprising insulin and EGF(A) analogues or derivatives thereof, and their pharmaceutical use. Furthermore, the invention relates to pharmaceutical compositions comprising such bi-functional compounds, and to the use of such compounds for the treatment or prevention of medical conditions relating to diabetes and dyslipidaemia associated with diabetes.
    Type: Application
    Filed: October 4, 2019
    Publication date: January 13, 2022
    Inventors: Martin Werner Borchsenius Muenzel, Susanne Hostrup, Gro Klitgaard Povlsen, Mathias Norrman, Thomas Boerglum Kjeldsen, Claudia Ulrich Hjoerringgaard, Peter Madsen
  • ErbB receptor-derived peptide fragments
    Patent number: 7897723
    Abstract: The invention relates to new peptide compounds capable of modulating cell proliferation, differentiation, survival and/or motility. The peptide compounds of the invention comprise short peptide fragments of the ErbB receptor and are capable of binding to ErbB and modulating activity of the receptor. The invention also relates to antibodies capable of binding to an epitope comprising a peptide sequence of the invention, pharmaceutical compositions comprising the peptide sequences and/or antibodies and uses thereof for treatment of conditions wherein modulating activity of ErbB is needed.
    Type: Grant
    Filed: April 3, 2007
    Date of Patent: March 1, 2011
    Assignee: Københavns Universitet
    Inventors: Elisabeth Bock, Vladimir Berezin, Gro Klitgaard Povlsen
  • Erbb Receptor-Derived Peptide Fragments
    Publication number: 20090092617
    Abstract: The invention relates to new peptide compounds capable of modulating cell proliferation, differentiation, survival and/or motility. The peptide compounds of the invention comprise short peptide fragments of the ErbB receptor and are capable of binding to ErbB and modulating activity of the receptor. The invention also relates to antibodies capable of binding to an epitope comprising a peptide sequence of the invention, pharmaceutical compositions comprising the peptide sequences and/or antibodies and uses thereof for treatment of conditions wherein modulating activity of ErbB is needed.
    Type: Application
    Filed: April 3, 2007
    Publication date: April 9, 2009
    Inventors: Elisabeth Bock, Vladimir Berezin, Gro Klitgaard Povlsen